The Lundquist Institute investigator Dr. Matthew Budoff presented results at AHA conference
Study shows The Lundquist Institute is top-tier venue for pharmaceutical research
PHILADELPHIA — Findings from a new study provide a promising pathway toward reducing the impact of heart disease, as the data shows that Vascepa, a drug derived from omega-3 oils that is commonly used to treat hypertriglyceridemia, a disease that causes elevated fat levels in blood, also reduces the progression of heart disease.
Leading Biomedical Innovators Honored at The Lundquist Institute Legends Celebration 2019
LOS ANGELES – The Lundquist Institute, one of the nation’s leading nonprofit biomedical research institutes, hosted its 16th Annual Legends celebration on November 12 honoring two highly distinguished researchers for their groundbreaking innovations and outstanding service in finding solutions to the most pressing medical problems of our day.
E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute (formerly known as LA BioMed) and the University of Rochester.
LOS ANGELES — E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute (formerly known as LA BioMed) and the University of Rochester.
Dr. Sherwin Isenberg’s life-changing research could prevent thousands of babies from going blind.
LOS ANGELES — Neonatal intensive care units (NICUs) are medical miracles, helping babies who would likely perish without technology and medical care, thrive. Alas, they often have a tragic side effect: many premature newborns in NICU units develop blindness. This blindness results from a condition called Retinopathy of Prematurity (ROP), caused when infants are exposed to normal or excessive supplementary oxygen, a common necessity in the NICU.
Funding launches study on link between healthy lifestyles and sperm quality
LOS ANGELES – A team of investigators from The Lundquist Institute (formerly known as LA BioMed), will receive $2.2 million of a total $7 million grant award from the National Institutes of Health (NIH) to research male reproductive health as part of a comprehensive study led by University of Nevada at Reno under the direction of Wei Yan, M.D., Ph.D.
About 20 percent of Americans of childbearing age face fertility problems. Of the 10 percent of infertile couples in the United States, one-third are due to the male’s infertility, according to the NIH.
24 of California’s top biotech startups shared their products at October 14 event
LOS ANGELES — Local startups working on everything from a device that diagnoses children’s ear infections with the push of a button, to a gene therapy for those susceptible to addiction that could replace opioids as a painkiller, to a diagnostic that can provide a highly specific analysis of cancerous lesions shared their groundbreaking innovations at the Lundquist Institute’s (formerly known as LA BioMed) sixth annual Innovation Showcase on October 14.
September 27 event focused on using latest research to deliver real-world results faster
LOS ANGELES — The Lundquist Institute (formerly known as LA BioMed) held its first Implementation Science Workshop on September 27, bringing dozens of California’s preeminent health care experts to its campus in an effort to promote better ways to bring latest research findings into routine medical practice faster, saving and improving countless lives.
The new biotech coworking space, BioLabs LA at The Lundquist, is ready to welcome innovative bioscience startups
LOS ANGELES — The Lundquist Institute, formerly the Los Angeles BioMedical Research Institute (LA BioMed), has launched the most advanced, state-of-the-art shared wet laboratory and office space facility in the Los Angeles region, BioLabs LA at The Lundquist.
Former Los Angeles Biomedical Research Institute Renamed After Historic $70 Million Gift
LOS ANGELES — The Los Angeles Biomedical Research Institute (LA BioMed) has been renamed the Lundquist Institute, after receiving the necessary approvals from its Board of Directors, the State of California, and other regulatory bodies. The institute’s new name is in honor of California philanthropists Melanie and Richard Lundquist, who pledged an unrestricted gift of $70 million in conjunction with their 70th birthdays earlier this year.
Dr. Richard Murphy is studying a new approach that shows promise for two deadly diseases
LOS ANGELES — Patients infected with both HIV and multidrug-resistant tuberculosis (MDR-TB) have historically had an uphill battle with low success rates and high mortality. Making things worse, until recently, the therapy for MDR-TB has been difficult, involving months of painful injections. But there’s a promising new oral treatment regimen for MDR-TB that could make a huge difference to patients in resource-limited settings.